Top

Published in:

01-12-2022 | Cholangiocarcinoma | Research

Crowberry inhibits cell proliferation and migration through a molecular mechanism that includes inhibition of DEK and Akt signaling in cholangiocarcinoma

Authors: Xue Wang, Xuebing Zhou, Ludan Zhang, Xin Zhang, Chunyu Yang, Yingshi Piao, Jinhua Zhao, Lili Jin, Guihua Jin, Renbo An, Xiangshan Ren

Published in: Chinese Medicine | Issue 1/2022

Abstract

Background

Cholangiocarcinoma (CCA) is a rare biliary adenocarcinoma related to poor clinical prognosis. Crowberry is an herbal medicine used to control inflammatory diseases and reestablish antioxidant enzyme activity. Although crowberry shows significant therapeutic efficacy in various tumors and diseases, its anticancer effects and specific molecular mechanisms in CCA are poorly understood.

Aim of the study

This study was conducted to characterize crowberry effects on CCA cells behavior.

Materials and methods

The chemical profiles of crowberry extract was qualitatively analyzed by high-performance liquid chromatography (HPLC) and HPLC–tandem mass spectrometry. MTT, colony formation and EdU assays were performed to measure cell proliferation. The effect of crowberry treatment on CCA cell migration was assessed by wound healing and migration assays. Moreover, Hoechst staining assay and flow cytometry were performed to assess the cell apoptosis rate. Western blotting was used to assess the protein expression levels of key factors associated with apoptosis, the Akt signaling pathway, and the epithelial-mesenchymal transition. A xenograft model was established and immunohistochemical and H&E staining was performed to assess crowberry antitumor effects in vivo.

Results

Crowberry clearly inhibited CCA cells proliferation and migration in a dose-dependent manner and induced apoptosis in vitro. Crowberry inactivated the PI3K/Akt signaling pathway by regulating DEK in vitro and significantly inhibited tumor growth by downregulating the DEK expression in xenograft models.

Conclusion

Crowberry inhibits CCA cells proliferation and migration through a molecular mechanism that includes inhibition of DEK and Akt signaling pathway inhibition in vitro and in vivo.

Graphical Abstract

Available only for authorised users

Doherty B, Nambudiri VE, Palmer WC. Update on the Diagnosis and Treatment of Cholangiocarcinoma. Curr Gastroenterol Rep. 2017;19(1):2. https://doi.org/10.1007/s11894-017-0542-4.CrossRefPubMed

Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15(2):95–111. https://doi.org/10.1038/nrclinonc.2017.157.CrossRefPubMed

Koskela AK, Anttonen MJ, Soininen TH, Saviranta NM, Auriola S, Julkunen TR, Karjalainen RO. Variation in the anthocyanin concentration of wild populations of crowberries (Empetrum nigrum L. subsp hermaphroditum). J Agric Food Chem. 2010;58(23):12286–91. https://doi.org/10.1021/jf1037695.CrossRefPubMed

Park SY, Lee ES, Han SH, Lee HY, Lee S. Antioxidative effects of two native berry species, Empetrum nigrum var japonicum K. Koch and Rubus buergeri Miq, from the Jeju Island of Korea. J Food Biochem. 2011;36(6):675–82. https://doi.org/10.1111/j.1745-4514.2011.00582.x.CrossRef

Claudia M, Fabíola C, Anna MP, Mysore VT, Martins MCL. Prevention of urinary catheter-associated infections by coating antimicrobial peptides from crowberry endophytes. Sci Rep. 2019;9(1):10753. https://doi.org/10.1038/s41598-019-47108-5.CrossRef

Kim KC, Kim D, Kim SC, Jung E, Park D, Hyun JW. Empetrum nigrum var japonicum extract suppresses ultraviolet B-induced cell damage via absorption of radiation and inhibition of oxidative stress. Evid Based Complement Alternat Med. 2013. https://doi.org/10.1155/2013/983609.CrossRefPubMedPubMedCentral

Ming Z, Shu LH, Dan W, Jun L, Jin LW, Li MB, Shun JZ. Chalcones from Empetrum nigrum var. Japonicum. Chinese Tradit Herbal Drugs. 2016;47(24):4318–21. https://doi.org/10.7501/j.issn.0253-2670.2016.24.003.CrossRef

Tunde JJM, Sona S, Stefan B, Jiri S, Mojmir B, Daniela S. Black Crowberry (Empetrum nigrum L.) Flavonoids and Their Health Promoting Activity. Molecules. 2016;21(12):1685. https://doi.org/10.3390/molecules21121685.CrossRef

León-González AJ, López-Lázaro M, Espartero JL, Martín-Cordero C. Cytotoxic activity of dihydrochalcones isolated from Corema album leaves against HT-29 colon cancer cells. Nat Prod Commun. 2013;8(9):1255–6. https://doi.org/10.1177/1934578X1300800918.CrossRefPubMed

10.

Li CY. Study on the preventive effect of Northeast Yangaolan on alcoholic fatty liver in rats. Master Dissertation, Heilongjiang University of Chinese Medicine, China, 2009. http://kns.cnki.net/kns/detail/detail.aspx?FileName=2009175615.nh&DbName=CMFD2009 (Accessed 2021–10–08).

11.

Yong T, Li WL, Catherine EJ. The Complexity of DEK signaling in cancer progression. Curr Cancer Drug Targets. 2018;18(3):256–65. https://doi.org/10.2174/1568009617666170522094730.CrossRef

12.

Yang MQ, Bai LL, Wang Z, Lei L, Zheng YW, Li ZH, Huang WJ, Liu CC, Xu HT. DEK is highly expressed in breast cancer and is associated with malignant phenotype and progression. Oncol Lett. 2021;21(6):440. https://doi.org/10.3892/ol.2021.12701.CrossRefPubMedPubMedCentral

13.

Huo CY, Hong BD. Wen SS, Zheng JL, Ya LL. DEK overexpression is predictive of poor prognosis in esophageal squamous cell carcinoma. Arch Med Sci. 2019; 17(1):135–141. DOI: https://doi.org/10.5114/aoms.2019.84210.

14.

Ting Z, Bi JQ, Sen HZ, Guo PD, Li PC, Zheng RW. Expression of DEK in pancreatic cancer and its correlation with clinicopathological features and prognosis. J Cancer. 2019;10(4):911–7. https://doi.org/10.7150/jca.27405.CrossRef

15.

Soo YL, Wonkyung J, Jinhwan L, Aeree K, Han KK, Baek-Hui K. High expression of DEK is associated with poor prognosis in hepatocellular carcinoma. Histol Histopathol. 2019;34(11):1279–88. https://doi.org/10.14670/HH-18-125.CrossRef

16.

Feng YT, Yu HW, Brian AH, Curzio R, Gong DX. PKB/Akt-dependent regulation of inflammation in cancer. Semin Cancer Biol. 2018;48:62–9. https://doi.org/10.1016/j.semcancer.2017.04.018.CrossRef

17.

Michael R, Duggan Michael W, Kamel K. PAM (PIK3/AKT/mTOR) signaling in glia: potential contributions to brain tumors in aging. Aging. 2021;13(1):1510–27. https://doi.org/10.18632/aging.202459.CrossRef

18.

Jiang M, Wu YL, Li X, Zhang YU, Xia KL, Cui BW, Li A, Li H, Nan JX. Oligomeric proanthocyanidin derived from grape seeds inhibited NFkB signaling in activated HSC: Involvement of JNK/ERK MAPK and PI3K/Akt pathways. Biomed Pharmacother. 2017;93:674–80. https://doi.org/10.1016/j.biopha.2017.06.105.CrossRefPubMed

19.

Yang Y, Gao M, Lin Z, Chen L, Jin Y, Zhu G, Wang Y, Jin T. DEK promoted EMT and angiogenesis through regulating PI3K/AKT/mTOR pathway in triple-negative breast cancer. Oncotarget. 2017;8(58):98708–22. https://doi.org/10.18632/oncotarget.21864.CrossRefPubMedPubMedCentral

20.

Yan AZ, Jie L, Shi BW, Xiao LL, Yang L, Zhao HL, Jie Z, Jing L, Li HD, Qin Y. The DEK oncogene activates VEGF expression and promotes tumor angiogenesis and growth in HIF-1α-dependent and -independent manners. Oncotarget. 2016;7(17):23740–56. https://doi.org/10.18632/oncotarget.8060.CrossRef

21.

Diepenbruck M, Christofori G. Epithelial-mesenchymal transition (EMT) and metastasis: yes, no, maybe. Curr Opin Cell Biol. 2016;43:7–13. https://doi.org/10.1016/j.ceb.2016.06.002.CrossRefPubMed

22.

Nye J, Melters DP, Dalal Y. The Art of War: harnessing the epigenome against cancer. F1000 Res. 2018;7:141. https://doi.org/10.12688/f1000research.12833.1.CrossRef

23.

Wu X, Wu G, Wu Z, Yao X, Li G. MiR-200a suppresses the proliferation and metastasis in pancreatic ductal adenocarcinoma through downregulation of DEK Gene. Trans Oncol. 2016;9(1):25–31. https://doi.org/10.1016/j.tranon.2015.11.005.CrossRef

24.

Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. New horizons for precision medicine in biliary tract cancers. Cancer Discov. 2016;7(9):943–62. https://doi.org/10.1158/2159-8290.CD-17-0245.CrossRef

25.

Pedro MR, Paula O, Nuno AP, Irene O, Alona AL, Ana L, Luis B, Maria JP, Jesus MB. Pathogenesis of Cholangiocarcinoma. Annu Rev Pathol. 2021;16:433–63. https://doi.org/10.1146/annurev-pathol-030220-020455。.CrossRef

26.

Woo CC, Kumar AP, Sethi G, Tan KH. Thymoquinone:potential cure for inflammatory disorders and cancerl. Biochem Pharmacol. 2012;83(4):443–51. https://doi.org/10.1016/j.bcp.2011.09.029.CrossRefPubMed

27.

Zhang Y, Chen J, Ma XM, Shi YP. Simultaneous determination of flavonoids in Ixeridium gracile by micellar electrokinetic chromatography. J Pharm and Biomed Anal. 2007;45(5):742–6. https://doi.org/10.1016/j.jpba.2007.08.014.CrossRef

28.

Sheng Y, Zou M, Wang Y, Li Q. 2’,4’-dihydroxychalcone, a flavonoid isolated from Herba oxytropis, suppresses PC-3 human prostate cancer cell growth by induction of apoptosis. Oncol Lett. 2015;10(6):3737–41. https://doi.org/10.3892/ol.2015.3795.CrossRefPubMedPubMedCentral

29.

Pistritto G, Trisciuoglio D, Ceci C, Garufi A, D’Orazi G. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. Aging. 2016;8(4):603–19. https://doi.org/10.18632/aging.100934.CrossRefPubMedPubMedCentral

30.

Hetz C, Vitte PA, Bombrun A, Rostovtseva TK, Montessuit S, Hiver A, Schwarz MK, Churc DJ, Korsmeyer SJ, Martinou JC, Antonsson B. Bax channel inhibitors prevent mitochondrion- mediated apoptosis and protect neurons in a model of global brain ischemia. J Biol Chem. 2005;280(52):42960–70. https://doi.org/10.1074/jbc.M505843200.CrossRefPubMed

31.

Slee EA, Adrain C, Martin SJ. Serial killers: ordering caspase activation events in apoptosis. Cell Death Differ. 1999;6(11):1067–74. https://doi.org/10.1038/sj.cdd.4400601.CrossRefPubMed

32.

Wang YF, Chen C, Yang C, Li H, Yang YX. Effects of 6-Shogoal on the apoptosis of human colorectal cancer cells and the expression of bax, bcl2, caspase 3 and PARP1. Modern Food Technology. 2017;33(11):7–15. https://doi.org/10.13982/j.mfst.1673-9078.2017.11.002.CrossRef

33.

Riveiro FE, Soengas MS. Control of tumorigenesis and chemoresistance by the DEK oncogene. Clin Cancer Res. 2010;16(11):2932–8. https://doi.org/10.1158/1078-0432.CCR-09-2330.CrossRef

34.

Yu L, Huang X, Zhang W, Zhao H, Wu G, Lv F, Shi L, Teng Y. Critical role of DEK and its regulation in tumorigenesis and metastasis of hepatocellular carcinoma. Oncotarget. 2016;7(18):26844–55. https://doi.org/10.18632/oncotarget.8565.CrossRefPubMedPubMedCentral

35.

Liu T, Zhu G, Yan W, Lv Y, Wang X, Jin G, Cui M, Lin Z, Ren X. Cordycepin inhibits cancer cell proliferation and angiogenesis through a DEK Interaction via ERK Signaling in Cholangiocarcinoma. J Pharmacol Exp Ther. 2020;373(2):279–89. https://doi.org/10.1124/jpet.119.263202.CrossRefPubMed

36.

Zhao M, Ang L, Huang J, Wang J. MicroRNAs regulate the epithelial–mesenchymal transition and influence breast cancer invasion and metastasis. Tumor Biol. 2017;39(2):101042831769168. https://doi.org/10.1177/1010428317691682.CrossRef

37.

Sven J, Jamie A, Dominic DG, Kyra C, Geert B, Steven G. Epithelial-Mesenchymal Transition (EMT) as a Therapeutic Target. Cells Tissues Organs. 2021;5:1–26. https://doi.org/10.1159/000512218.CrossRef

38.

Wang YP, Wang QY, Li CH, Li XW. COX-2 inhibition by celecoxib in epithelial ovarian cancer attenuates E-cadherin suppression through reduced Snail nuclear translocation. Chem Biol Interact. 2018;292:24–9. https://doi.org/10.1016/j.cbi.2018.06.020.CrossRefPubMed

39.

Xu X, Zou L, Yao Q, Zhang Y, Gan L, Tang L. Silencing DEK downregulates cervical cancer tumorigenesis and metastasis via the DEK/p-Ser9-GSK-3β/p-Tyr216-GSK-3β/β-catenin axis. Oncol Rep. 2017;38(2):1035–42. https://doi.org/10.3892/or.2017.5721.CrossRefPubMed

40.

Yang MQ, Bai LL, Lei L, Zheng YW, Wang Z, Li ZH, Liu CC, Huang WJ, Xu HT. DEK promotes the proliferation and invasion of lung cancers and indicates poor prognosis in lung adenocarcinomas. Oncol Rep. 2020;43(4):1338–48. https://doi.org/10.3892/or.2020.7488.CrossRefPubMed

41.

Chen J, Zhao KN, Li R, Shao RF, Chen C. Activation of PI3K/Akt/mTOR pathway and dual inhibitors of PI3K and mTOR in endometrial cancer. Curr Medl Chem. 2014;21(26):3070–80. https://doi.org/10.2174/0929867321666140414095605.CrossRef

42.

Hui H, Hong YZ, Jing ZC, Jiao W, Jie Y, Yang FJ. Targeting Akt in cancer for precision therapy. J Hematol Oncol. 2021;14(1):128. https://doi.org/10.1186/s13045-021-01137-8.CrossRef

43.

Corti F, Nichetti F, Raimondi A, Niger M, Prinzi N, Torchio M, Tamborini E, Perrone F, Pruneri G, Di Bartolomeo M, de Braud F. Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: a review of current evidences and future perspectives. Cancer Treatment Rev. 2019;72:45–55. https://doi.org/10.1016/j.ctrv.2018.11.001.CrossRef

44.

Bishwanath A, Wanna C, Kesara NB. Atractylodin inhibited the migration and induced autophagy in cholangiocarcinoma cells via PI3K/AKT/mTOR and p38MAPK signalling pathways. J Pharm Pharmacol. 2021;73(9):1191–200. https://doi.org/10.1093/jpp/rgab036.CrossRef

45.

Capitano ML, Nirit MV, Anjan KS, Scott C, Maureen L, Haihong G, Rafael CG, Ferdinand K, Maureen AS, Christopher TL, Xin XH, David MM, Hal EB. Secreted nuclear protein DEK regulates hematopoiesis through CXCR2 signaling. J Clin Invest. 2019;129(6):2555–70. https://doi.org/10.1172/JCI127460.CrossRefPubMedPubMedCentral

46.

Yan JC, Jee Y, Jin JW, Ji HL, Yoon SY, Moon SK, Sung CJ, Joo MP, Eun SY, Seong HK, Sangmee AJ, Kyoungho S, Su YE. Dieckol Attenuates Microglia-mediated Neuronal Cell Death via ERK, Akt and NADPH Oxidase-mediated Pathways. Korean J Physiol Pharmacol. 2015;19(3):219–28. https://doi.org/10.4196/kjpp.2015.19.3.219.CrossRef

47.

Xue XC, Xian W, Wen O, Min G, Zi LG, Ming YS, Yun JC, Yan YL, Yong C, Hang X. Novel ent-Kaurane Diterpenoid From Rubus Corchorifolius L. F. Inhibits Human Colon Cancer Cell Growth via Inducing Cell Cycle Arrest and Apoptosis. J Agric Food Chem. 2017;65(8):1566–73. https://doi.org/10.1021/acs.jafc.6b05376.CrossRef

48.

Te SL.The mechanisms of Cordycepin suppresses cell prohferatl07 n and migration by targeting DEK in cholangiocarcinoma via Akt and Erkl/2 signaling pathway. Master Dissertation, Yanbian University, China, 2018. https://kns.cnki.net/kns8/defaultresult/index (Accessed 08 Oct 2021).

49.

Mostafa KR, Arash S, Anvar S, Kolsoum RK, Amir RA, Mohammad S. Role of AKT and mTOR signaling pathways in the induction of epithelial-mesenchymal transition (EMT) process. Biochimie. 2019;165:229–34. https://doi.org/10.1016/j.biochi.2019.08.003.CrossRef

50.

Yi LS, Zhi GW, Jing ZJ, Yi HP, Li L, Chang X, Hong MP, Liang CL, Guang HY. DEK-targeting aptamer DTA-64 attenuates bronchial EMT-mediated airway remodelling by suppressing TGF-β1/Smad, MAPK and PI3K signalling pathway in asthma. J Cell and Mol Med. 2020;24(23):13739–50. https://doi.org/10.1111/jcmm.15942.CrossRef

51.

HUA Y, HU HG, PENG XL. Progress in studies on the DEK protein and its involvement in cellular apoptosis. Sci China Ser C-Life Sci. 2009; 52(7):637–642. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&dbname=CJFD2009&filename=JCXG200907008&uniplatform=NZKPT&v=Cdf2cXeH8K64rF-z1HIJXH6axYUCEBczcE_ESHSj8jpXeP3cwES5X4-_ok_5DxPk.CrossRefPubMed

52.

Kim YY, Jee HJ, Um JH, Kim YM, Bae SS, Yun J. Cooperation between p21 and Akt is required for p53-dependent cellular senescence. Aging Cell. 2017; 16(5): 1094–1103. https://doi.org/10.1111/acel.12639.CrossRefPubMedPubMedCentral

Title: Crowberry inhibits cell proliferation and migration through a molecular mechanism that includes inhibition of DEK and Akt signaling in cholangiocarcinoma
Authors: Xue Wang
Xuebing Zhou
Ludan Zhang
Xin Zhang
Chunyu Yang
Yingshi Piao
Jinhua Zhao
Lili Jin
Guihua Jin
Renbo An
Xiangshan Ren
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Cholangiocarcinoma
Cholangiocarcinoma
Published in: Chinese Medicine / Issue 1/2022
Electronic ISSN: 1749-8546
DOI: https://doi.org/10.1186/s13020-022-00623-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Crowberry inhibits cell proliferation and migration through a molecular mechanism that includes inhibition of DEK and Akt signaling in cholangiocarcinoma

Abstract

Background

Aim of the study

Materials and methods

Results

Conclusion

Graphical Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Aim of the study

Materials and methods

Results

Conclusion

Graphical Abstract

Please log in to get access to this content

Other articles of this Issue 1/2022

A review on the applications of Traditional Chinese medicine polysaccharides in drug delivery systems

Combination of curcumin and piperine synergistically improves pain-like behaviors in mouse models of pain with no potential CNS side effects

Improvement of polydopamine-loaded salidroside on osseointegration of titanium implants

Chinese herbal medicine treatment based on subgroup differentiation as adjunct therapy for Parkinson’s disease: study protocol of a pilot add-on, randomised, controlled, pragmatic clinical trial

Combination of pseudoephedrine and emodin ameliorates LPS-induced acute lung injury by regulating macrophage M1/M2 polarization through the VIP/cAMP/PKA pathway

Three-dimensional visualization of electroacupuncture-induced activation of brown adipose tissue via sympathetic innervation in PCOS rats